Home > Neurology > EAN 2020 > Neuromuscular Disorders > Efficacy and safety of rituximab in refractory MG corroborated

Efficacy and safety of rituximab in refractory MG corroborated

Presented By
Dr A Dos Santos, University Hospital of Nantes, France
Conference
EAN 2020
In a French retrospective multicentre study, the efficacy and safety of rituximab as a second-line immunosuppressive treatment of steroid-dependent myasthenia gravis (MG) was corroborated [1]. Thus far, the probable benefit was based on a few small studies and anecdotal evidence. Inclusion criteria for this retrospective study were age >18 years, MG with acetylcholine receptor (AchR) antibodies, MuSK antibodies, or significant decrement on single-fibre electromyography, MG Foundation of America (MGFA) score >II, refractory or steroid-dependent MG, and rituximab treatment. Included were 27 patients from 6 French neurology centres: 19 had AchR-antibody-positive MG, 4 MuSK-antibody-positive MG, and 2 had seronegative MG. MGFA post-interventional score had improved in 81.4% of patients after 6 months of treatment (P<0.0001). A second measure of efficacy, the mean Garches’ score, increased from 65.29 to 84.23 after 6 months (P<0.0001). A thir...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on